KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome [Seeking Alpha]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Seeking Alpha
KALV maintains a Strong Buy rating, driven by EKTERLY's $49.1M in 2025 sales and positive pediatric phase 3 KONFIDENT-KID interim results. EKTERLY is the first and only oral on-demand HAE therapy, with expansion into pediatric patients and multiple global markets underway. Key KALV risks include sNDA approval uncertainty for pediatric use, sustainability of EKTERLY sales, and successful Chiesi deal closure. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » FabrikaCr/iStock via Getty Images The last time I spoke about KalVista Pharmaceuticals, Inc. ( KALV ), it was with a Seeking Alpha article entitled " KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion ." With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you r
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement [Yahoo! Finance]Yahoo! Finance
- Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public ShareholdersPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)GlobeNewswire
- KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its ShareholdersBusiness Wire
KALV
Earnings
- 3/25/26 - Miss
KALV
Sec Filings
- 4/29/26 - Form SC14D9C
- 4/29/26 - Form 8-K
- 4/20/26 - Form 4
- KALV's page on the SEC website